Is Glasdegib a targeted drug?

Glasdegib is an oral small molecule drug that belongs to the category of targeted therapy drugs and mainly acts on the Hedgehog signaling pathway. The Hedgehog pathway is critical in embryonic development but is abnormally activated in certain cancer types, leading to tumor cell proliferation and survival. Glassgib inhibits tumor growth by inhibiting Smoothened (SMO), a key molecule in the Hedgehog pathway, preventing cancer cell signaling. Due to its specific mechanism of action, it is classified as a Hedgehog pathway inhibitor (HPI) and shows good potential in the treatment of acute myeloid leukemia (AML).

Clinical studies have shown that in some AML patients, the Hedgehog signaling pathway is abnormally active, allowing leukemia stem cells to evade clearance by the immune system and maintain their ability to proliferate. By targeting this pathway, Glasgib reduces the ability of malignant cells to self-renew, thereby increasing patients' sensitivity to chemotherapy. Therefore, it is often used in combination with low-dose cytarabine (LDAC) to enhance therapeutic efficacy. It is worth noting that unlike traditional cytotoxic chemotherapy, Glasgib is more selective and mainly targets cancer cells with abnormally activated Hedgehog signaling, while having less impact on normal cells, so the side effects are relatively mild and easier to tolerate.

Although Glasgib is a targeted drug, it does not directly act on the genetic mutations of tumors like some tyrosine kinase inhibitors (TKIs) or immune checkpoint inhibitors. Instead, it inhibits cancer cells by interfering with the cancer microenvironment and signaling. Therefore, in some cases, it may need to be combined with other treatments, such as chemotherapy or immunotherapy, to achieve optimal treatment results. In summary, Glasgib, as a Hedgehog signaling pathway inhibitor, plays a unique role in the treatment of AML patients, providing a new treatment option for elderly patients or patients with weak constitutions who cannot tolerate high-intensity chemotherapy.

Reference materials:https://www.ncbi.nlm.nih.gov/books/NBK548156/